{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:06Z","timestamp":1790626266492,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>New users of gabapentin and pregabalin were identified from June 2006 to December 2014, and new users of duloxetine served as control group. Misuse was defined as a use of higher daily doses than recommended. Cox proportional hazard regression models were performed to identify associated factors of misuse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Misuse was more frequent in the 8692 new users of pregabalin (12.8%) than in the 1963 gabapentin (6.6%) or the 3214 duloxetine new users (9.7%) (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001). Factors associated with misuse were pregabalin (hazard ratio [HR] 1.48; 95% confidence interval [CI] [1.29\u20131.69]), age (HR<jats:sub>[18\u201345]\u00a0versus\u00a0&gt;\u00a070\u00a0years<\/jats:sub> 1.98 [1.70\u20132.31] and HR<jats:sub>[58\u201370]\u00a0versus\u00a0&gt;\u00a070\u00a0years<\/jats:sub> 1.25 [1.06\u20131.47]), multiple prescribers (HR<jats:sub>2\u00a0or\u00a03\u00a0versus\u00a01\u00a0prescriber<\/jats:sub> 1.29 [1.15\u20131.45]; HR<jats:sub>4\u00a0or\u00a0more\u00a0versus\u00a01\u00a0prescriber<\/jats:sub> 1.54 [1.30\u20131.83]), cancer (1.28 [1.11\u20131.47]), multiple sclerosis (1.53 [1.07\u20132.18]), neuropathy (1.85 [1.19\u20132.89]), depression (1.26 [1.07\u20131.49]) and methadone (2.61 [1.16\u20135.84]). After this first episode of drug misuse, 11.6% of gabapentin and 10.7% of pregabalin misusers developed a primary addiction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a cohort of new users, misuse is more likely to occur in new users of pregabalin, with different associated factors of misuse compared to gabapentin and duloxetine. Health professionals and prescribers must be aware of this misuse potential, which could lead to abuse and dependence.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13892","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T06:38:39Z","timestamp":1549694319000},"page":"1260-1269","source":"Crossref","is-referenced-by-count":104,"title":["Patterns of gabapentin and pregabalin use and misuse: Results of a population\u2010based cohort study in France"],"prefix":"10.1111","volume":"85","author":[{"given":"Damien","family":"Driot","sequence":"first","affiliation":[{"name":"D\u00e9partement universitaire de m\u00e9decine g\u00e9n\u00e9rale, Facult\u00e9 de M\u00e9decine Universit\u00e9 de Toulouse  France"},{"name":"Unit\u00e9 Mixte de Recherche, 1027 Inserm\u2010Universit\u00e9, Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-2475","authenticated-orcid":false,"given":"Emilie","family":"Jouanjus","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche, 1027 Inserm\u2010Universit\u00e9, Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  France"},{"name":"Centre d'Evaluation et d'Information sur la Pharmacod\u00e9pendance\u2014Addictovigilance (CEIP) Service de Pharmacologie M\u00e9dicale et Clinique  CHU de Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oustric","sequence":"additional","affiliation":[{"name":"D\u00e9partement universitaire de m\u00e9decine g\u00e9n\u00e9rale, Facult\u00e9 de M\u00e9decine Universit\u00e9 de Toulouse  France"},{"name":"Unit\u00e9 Mixte de Recherche, 1027 Inserm\u2010Universit\u00e9, Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dupouy","sequence":"additional","affiliation":[{"name":"D\u00e9partement universitaire de m\u00e9decine g\u00e9n\u00e9rale, Facult\u00e9 de M\u00e9decine Universit\u00e9 de Toulouse  France"},{"name":"Unit\u00e9 Mixte de Recherche, 1027 Inserm\u2010Universit\u00e9, Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre\u2010Mestre","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche, 1027 Inserm\u2010Universit\u00e9, Pharmaco\u00e9pid\u00e9miologie Universit\u00e9 de Toulouse  France"},{"name":"Centre d'Evaluation et d'Information sur la Pharmacod\u00e9pendance\u2014Addictovigilance (CEIP) Service de Pharmacologie M\u00e9dicale et Clinique  CHU de Toulouse France"},{"name":"Centre d'Investigation Clinique, 1436 Inserm CHU  CHU de Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"CD010567","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia\u2014An overview of Cochrane reviews","volume":"11","author":"Wiffen PJ","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.04.004"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13879"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321079"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0359-y"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13324"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355268"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12277"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4230"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-016-9421-7"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2017.402"},{"key":"e_1_2_9_15_1","unstructured":"Pregabalin and gabapentin to be controlled as class C drugs. UK government 2018.https:\/\/www.gov.uk\/government\/news\/pregabalin\u2010and\u2010gabapentin\u2010to\u2010be\u2010controlled\u2010as\u2010class\u2010c\u2010drugs. Accessed February 21 2019."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0853-y"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e3182872718"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.04.006"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1578-5"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0303-6"},{"issue":"10","key":"e_1_2_9_22_1","first-page":"309","article-title":"Pregabalin abuse amongst opioid substitution treatment patients","volume":"108","author":"McNamara S","year":"2015","journal-title":"Ir Med J"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-101868"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1594-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13408"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2010.04.005"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2014.11.009"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12214"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2010.00882.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4123"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.006"},{"key":"e_1_2_9_33_1","unstructured":"SmithRV.Exploration of the misuse abuse and diversion of gabapentin. PhD dissertation University of Kentucky 2016."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.05.053"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13882"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k959"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-30"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0920-4"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.03.009"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"issue":"1","key":"e_1_2_9_42_1","first-page":"89","article-title":"Doctor shopping reveals geographical variations in opioid abuse","volume":"16","author":"Nordmann S","year":"2013","journal-title":"Pain Physician"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13111526"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0164-4"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X653516"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02792.x"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00120.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2010.00590.x"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2015006"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12159"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.013"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-012-0006-6"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0421-z"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1615-7"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531570-000000000-00000"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2011.00950.x"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.036"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:12:34Z","timestamp":1694329954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bcp.13892"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13892","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]}}}